Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis

被引：0

作者：

Hauser, S. ^{[1
]}

Comi, G. ^{[2
]}

Hartung, H. -P. ^{[3
]}

Selmaj, K. ^{[4
]}

Traboulsee, A. ^{[5
]}

Bar-Or, A. ^{[6
]}

Arnold, D. ^{[6
]}

Klingelschmitt, G. ^{[7
]}

Leppert, D. ^{[8
]}

Kakarieka, A. ^{[8
]}

Lublin, F. ^{[9
]}

Garren, H. ^{[8
]}

Kappos, L. ^{[10
]}

机构：

[1] UCSF, Neurosci, San Francisco, CA USA

[2] Sci Inst HS Raffaele, Neurol, Milan, Italy

[3] Univ Dusseldorf, Neurosci, Dusseldorf, Germany

[4] Med Univ Lodz, Neurol, Lodz, Poland

[5] Univ British Columbia, Multiple Sclerosis Clin, Vancouver, BC V5Z 1M9, Canada

[6] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada

[7] F Hoffmann La Roche, Biometr, Basel, Switzerland

[8] F Hoffmann La Roche, Neurosci, Basel, Switzerland

[9] Mt Sinai Hosp, Neurol, New York, NY 10029 USA

[10] Univ Basel Hosp, CH-4031 Basel, Switzerland

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

F3139

引用

页码：752 / 752

页数：1